LEVERKUSEN (dpa-AFX) - German pharmaceutical and life sciences major Bayer
(BAYZF.PK, BAYRY.PK, BYR.L) reported that its net income for the first quarter
declined to 2.00 billion euros or 2.04 euros per share from 2.18 billion euros
or 2.22 euros per share in the same quarter last year.

Core earnings per share from continuing operations for the first quarter
decreased to 2.82 euros from last year's 2.95 euros, mainly due to the decline
in earnings at the Crop Science Division.

Group sales were 13.77 billion euros in the first quarter of 2024, representing
a decline of 0.6% on a currency- and portfolio-adjusted basis (Fx & portfolio
adj.), and a decline of 4.3% on a reported basis.

Bayer has confirmed its currency-adjusted forecast for full-year 2024.i.e. based
on the average monthly exchange rates in 2023. However, the negative impact from
anticipated currency effects has increased based on the closing rates as of
March 31, 2024. Applying the rates on that closing date instead of December 31,
2023, leads to a reduction in the forecast for EBITDA before special items from
between 10.4 billion and 11.0 billion euros to between 10.2 billion euros and
10.8 billion euros, for example.

The company now expects annual core earnings per share to be in the range of
4.80 euros to 5.20 euros compared to the prior outlook of 4.95 euros to 5.35
euros.

On a currency-adjusted basis, the company still expects core earnings per share
to be 5.10 euros to 5.50 euros for fiscal year 2024.

For more earnings news, earnings calendar, and earnings for stocks, visit
rttnews.com.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX